Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

179 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Induction of Peripheral Effector CD8 T-cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Non-small Cell Lung Cancer Patients.
de Goeje PL, Poncin M, Bezemer K, Kaijen-Lambers MEH, Groen HJM, Smit EF, Dingemans AC, Kunert A, Hendriks RW, Aerts JGJV. de Goeje PL, et al. Among authors: dingemans ac. Clin Cancer Res. 2019 Apr 1;25(7):2219-2227. doi: 10.1158/1078-0432.CCR-18-2243. Epub 2019 Jan 14. Clin Cancer Res. 2019. PMID: 30642911 Clinical Trial.
Immunoglobulin-like transcript 3 is expressed by myeloid-derived suppressor cells and correlates with survival in patients with non-small cell lung cancer.
de Goeje PL, Bezemer K, Heuvers ME, Dingemans AC, Groen HJ, Smit EF, Hoogsteden HC, Hendriks RW, Aerts JG, Hegmans JP. de Goeje PL, et al. Among authors: dingemans ac. Oncoimmunology. 2015 Mar 19;4(7):e1014242. doi: 10.1080/2162402X.2015.1014242. eCollection 2015 Jul. Oncoimmunology. 2015. PMID: 26140237 Free PMC article.
[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches.
de Jong EE, van Elmpt W, Leijenaar RT, Hoekstra OS, Groen HJ, Smit EF, Boellaard R, van der Noort V, Troost EG, Lambin P, Dingemans AC. de Jong EE, et al. Among authors: dingemans ac. Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):8-16. doi: 10.1007/s00259-016-3498-y. Epub 2016 Sep 6. Eur J Nucl Med Mol Imaging. 2017. PMID: 27600280 Free PMC article. Clinical Trial.
The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC.
Manegold C, Dingemans AC, Gray JE, Nakagawa K, Nicolson M, Peters S, Reck M, Wu YL, Brustugun OT, Crinò L, Felip E, Fennell D, Garrido P, Huber RM, Marabelle A, Moniuszko M, Mornex F, Novello S, Papotti M, Pérol M, Smit EF, Syrigos K, van Meerbeeck JP, van Zandwijk N, Yang JC, Zhou C, Vokes E. Manegold C, et al. Among authors: dingemans ac. J Thorac Oncol. 2017 Feb;12(2):194-207. doi: 10.1016/j.jtho.2016.10.003. Epub 2016 Oct 8. J Thorac Oncol. 2017. PMID: 27729297 Free article. Review.
Development of symptomatic brain metastases after chemoradiotherapy for stage III non-small cell lung cancer: Does the type of chemotherapy regimen matter?
Hendriks LEL, Brouns -JWM, Amini M, Uyterlinde W, Wijsman R, Bussink J, Biesma B, Oei SB, Stigt JA, Bootsma GP, Belderbos JSA, De Ruysscher DKM, Van den Heuvel MM, Dingemans AC. Hendriks LEL, et al. Among authors: dingemans ac. Lung Cancer. 2016 Nov;101:68-75. doi: 10.1016/j.lungcan.2016.09.008. Epub 2016 Sep 9. Lung Cancer. 2016. PMID: 27794410 Free article.
Management of stage I and II nonsmall cell lung cancer.
McDonald F, De Waele M, Hendriks LE, Faivre-Finn C, Dingemans AC, Van Schil PE. McDonald F, et al. Among authors: dingemans ac. Eur Respir J. 2017 Jan 3;49(1):1600764. doi: 10.1183/13993003.00764-2016. Print 2017 Jan. Eur Respir J. 2017. PMID: 28049169 Free article. Review.
Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter?
Derks JL, van Suylen RJ, Thunnissen E, den Bakker MA, Groen HJ, Smit EF, Damhuis RA, van den Broek EC, Speel EM, Dingemans AC; PALGA group. Derks JL, et al. Among authors: dingemans ac. Eur Respir J. 2017 Jun 1;49(6):1601838. doi: 10.1183/13993003.01838-2016. Print 2017 Jun. Eur Respir J. 2017. PMID: 28572122 Free PMC article.
Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer.
Yang JC, Ou SI, De Petris L, Gadgeel S, Gandhi L, Kim DW, Barlesi F, Govindan R, Dingemans AC, Crino L, Lena H, Popat S, Ahn JS, Dansin E, Golding S, Bordogna W, Balas B, Morcos PN, Zeaiter A, Shaw AT. Yang JC, et al. Among authors: dingemans ac. J Thorac Oncol. 2017 Oct;12(10):1552-1560. doi: 10.1016/j.jtho.2017.06.070. Epub 2017 Jul 6. J Thorac Oncol. 2017. PMID: 28689043 Free PMC article. Clinical Trial.
179 results